Cargando…

Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy

BACKGROUND: To evaluate the predictive value of AR-V7 expression detected by immunohistochemical (IHC) in the prognosis of prostate cancer patients receiving adjuvant hormonal therapy (AHT) following radical prostatectomy (RP). METHODS: We retrospectively collected data of 110 patients with prostate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ouyang, Wei, Zhang, Yucong, Long, Gongwei, Sun, Guoliang, Liu, Man, Li, Fan, Yang, Chunguang, Zeng, Xing, Yang, Jun, Yu, Xiao, Wang, Zhihua, Liu, Zheng, Guan, Wei, Hu, Zhiquan, Wang, Shaogang, Liu, Xiaming, Li, Heng, Xu, Hua, Ye, Zhangqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011087/ https://www.ncbi.nlm.nih.gov/pubmed/33789757 http://dx.doi.org/10.1186/s40364-021-00276-x

Ejemplares similares

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jiaxin, et al.
Publicado: (2020)

Robot-assisted laparoscopic partial nephrectomy is a safe and effective option for clinical T2 renal cell carcinoma: a case-series from single-institution
por: Long, Gongwei, et al.
Publicado: (2020)

Complete androgen blockade vs. medical castration alone as adjuvant androgen deprivation therapy for prostate cancer patients following radical prostatectomy: a retrospective cohort study
por: Jin, Di, et al.
Publicado: (2022)

Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation
por: Duan, Lingling, et al.
Publicado: (2019)

Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy
por: Ahn, Hyun Kyu, et al.
Publicado: (2020)

Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer
por: Sato, Yuzuri Tsurumaki, et al.
Publicado: (2014)

Spermatogenesis of Male Patients with Congenital Hypogonadotropic Hypogonadism Receiving Pulsatile Gonadotropin-Releasing Hormone Therapy Versus Gonadotropin Therapy: A Systematic Review and Meta-Analysis
por: Wei, Chao, et al.
Publicado: (2021)

Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients
por: Liu, Jinan, et al.
Publicado: (2013)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy
por: van Boxtel, Wim, et al.
Publicado: (2019)

Thulium Laser Resection of Bladder Tumors vs. Conventional Transurethral Resection of Bladder Tumors for Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer Followed by Intravesical BCG Immunotherapy
por: Liu, Zheng, et al.
Publicado: (2021)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
por: Wei, Yongbao, et al.
Publicado: (2023)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy
por: Li, Heng, et al.
Publicado: (2019)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer
por: Han, Sujun, et al.
Publicado: (2023)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022)

Assessment of oligometastasis status of prostate cancer following combined robot-assisted radical prostatectomy and androgen deprivation versus androgen deprivation therapy alone using PSA percentage decline rate
por: Li, Xuwen, et al.
Publicado: (2023)

Adjunctive medical expulsive therapy with tamsulosin for repeated extracorporeal shock wave lithotripsy: a systematic review and meta-analysis
por: Ouyang, Wei, et al.
Publicado: (2020)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy
por: Duan, Xiuzhi, et al.
Publicado: (2019)

Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy
por: Shin, Dongseong, et al.
Publicado: (2020)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Identification of a DNA Repair Gene Signature and Establishment of a Prognostic Nomogram Predicting Biochemical-Recurrence-Free Survival of Prostate Cancer
por: Long, Gongwei, et al.
Publicado: (2021)

CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling
por: Wang, Tao, et al.
Publicado: (2014)

Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study
por: Qin, Xiaojian, et al.
Publicado: (2015)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy
por: Maru, Shintaro, et al.
Publicado: (2018)

Safety first: evidence for delay of radical prostatectomy without use of androgen deprivation therapy during COVID-19
por: Sean Ong, Xuan Rui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fb3jmdategof9ovg10nh0f8mjr